# VIB-UGent Center for Inflammation Research

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/vib-ugent-center-for-inflammation-research/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71 |
| Citations | 766,994 |
| City | Ghent |
| Country | BE |
| Description | VIB-UGent Center for Inflammation Research is a research organisation in Ghent, BE. OpenAlex records 3,578 works and 766,994 citations for it. 702 researchers list it as their most recent affiliation. |
| Homepage | https://www.irc.ugent.be/ |
| OpenAlex ID | https://openalex.org/I4210139803 |
| Researchers | 702 |
| ROR ID | https://ror.org/04q4ydz28 |
| Type | facility |
| Works | 3,578 |

## University papers

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021](https://scholariq.org/papers/estimated-global-proportions-of-individuals-with-persistent-fatigue-cognitive/)
- [The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes](https://scholariq.org/papers/the-pd-1-pd-l1-checkpoint-restrains-t-cell-immunity-in-tumor-draining-lymph/)
- [Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)

## University top topics

Showing 8 of 25.

- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Immune Response and Inflammation](https://scholariq.org/topics/immune-response-and-inflammation/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.